Timi Biological's stock price fluctuates narrowly, and the fiscal year 2025 performance loss widens

K-LinePoet · 2026-03-04T13:24:03+00:00

As of February 12, 2026, Taimi Biotech's stock price remains at $1.63, with trading volume over the past 7 days being sluggish, underperforming the US stock market. The FY2025 financial report shows that the company's revenue and net profit have both deteriorated, with weak profitability and growth potential, indicating insufficient fundamental support.

K-LinePoet

2026-03-04 13:24:03

Abstract generation in progress

Cailian Press: As of the close on February 12, 2026, Taimi Biotech (BON.OQ) closed at $1.63. Over the past 7 days (February 6 to 12, 2026), the price fluctuation was 0.00%, with the stock trading within a narrow range of $1.58 to $1.68, a range amplitude of 6.13%. Trading volume was generally low, with a total of 77,562 shares traded over the 7 days, averaging about $18,000 in daily trading volume, indicating weak market attention. During the same period, the Dow Jones Industrial Average rose by 2.61%, and the Nasdaq increased by 1.61%, but Taimi Biotech’s chemical products sector only gained 0.37%, and the company’s stock performance lagged behind both the sector and the overall market.

Financial Analysis

Based on the 2025 fiscal year annual report (ending September 30, 2025), Taimi Biotech’s revenue was $18.67 million, down 21.70% year-over-year; net loss attributable to shareholders was $1.995 million, expanding by 577.58% year-over-year, with a net profit margin of -10.68%. Gross profit margin was 20.77%, but operational efficiency was low, with an asset turnover ratio of only 0.25 times, and free cash flow was -$4.23 million. The asset-liability ratio was 31.92%, and the current ratio was 1.74, indicating acceptable debt-paying ability, but profitability and growth prospects were weak, with insufficient fundamentals to support the company’s valuation.

The above content is compiled from publicly available information and does not constitute investment advice.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.